GlassScriptPhysician profile
Robin L Lipschitz
NPI 1891894655
$13,975.17
in general payments reported to CMS, 2019-2025
35 companies · $2,725 in 2025
The $2,725 reported for 2025 was more than what 75% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,783 · 2020: $1,499 · 2021: $768 · 2022: $1,989 · 2023: $2,637 · 2024: $2,575 · 2025: $2,725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,936.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,948.39 | 2019-2025 | Cimzia, Bimzelx |
| Abbvie INC. | $1,723.66 | 2019-2025 | |
| Amgen INC. | $1,587.71 | 2019-2025 | Enbrel, Otezla, Krystexxa |
| Pfizer INC. | $1,093.08 | 2019-2025 | |
| Janssen Biotech, INC. | $1,023.81 | 2019-2025 | Tremfya, Simponi, Remicade |
| Astrazeneca Pharmaceuticals LP | $907.66 | 2022-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $785.04 | 2019-2025 | Benlysta, Nucala |
| Lilly USA, LLC | $656.00 | 2019-2025 | Taltz, Olumiant |
| Mallinckrodt Hospital Products INC. | $391.61 | 2020-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $364.36 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $299.23 | 2019-2025 | Orencia, Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.77 | 2023-2025 | Ofev, Cyltezo, Jascayd |
| Genzyme Corporation | $197.37 | 2023-2024 | |
| Mallinckrodt Enterprises LLC | $194.42 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $188.50 | 2024 | Arcalyst |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $145.67 | 2020-2025 | Strensiq |
| Horizon Therapeutics Plc | $141.69 | 2019-2023 | Krystexxa |
| Janssen Scientific Affairs, LLC | $135.28 | 2024 | Tremfya |
| Aurinia Pharma U.S., INC. | $123.84 | 2023-2025 | Lupkynis |
| Actelion Pharmaceuticals US, INC. | $119.77 | 2022-2025 | Opsynvi, Opsumit |
| Cardinal Health 110 LLC | $100.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $80.69 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $79.67 | 2019 | |
| Genentech USA, INC. | $76.05 | 2023-2025 | Actemra |
| Ani Pharmaceuticals, INC. | $63.06 | 2024 | Purified Cortrophin Gel |
| Fresenius Kabi USA, LLC | $56.37 | 2023 | Idacio |
| Kyowa Kirin, INC. | $54.07 | 2023-2024 | Crysvita |
| Invivyd INC | $48.86 | 2025 | Pemgarda |
| Hikma Pharmaceuticals USA | $33.01 | 2023 | Mitigare |
| Depuy Synthes Sales INC. | $27.98 | 2019-2024 | Monovisc |
| Organon LLC | $22.67 | 2025 | Hadlima |
| Scilex Pharmaceuticals INC. | $22.66 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $17.16 | 2023 | Arcalyst |
| Sobi, INC | $15.95 | 2025 | |
| Antares Pharma, INC. | $14.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Lipschitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.